Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exscientia Plc (EXAI)
NASDAQ:EXAI
Holding EXAI?
Track your performance easily
EXAI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.80 - $7.91
Previous Close$5.44
Volume596.60K
Average Volume (3M)628.91K
Market Cap
$670.65M
Enterprise Value$426.79M
Total Cash (Recent Filing)$361.15M
Total Debt (Recent Filing)$117.29M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Nov 13, 2024EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding125,702,396
10 Day Avg. Volume482,419
30 Day Avg. Volume628,910
Standard Deviation0.19
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.92
Price to Sales (P/S)24.68
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue27.61
Enterprise Value/Gross Profit-58.27
Enterprise Value/Ebitda-7.24
Forecast
1Y Price Target
$5.35Price Target Upside-1.65% Downside
Rating ConsensusHold
Number of Analyst Covering3
Exscientia Plc News
PremiumCompany Announcements
Exscientia Plc Faces Financial Challenges Amid Rising Costs
PremiumCompany Announcements
Exscientia Plc Enhances Board Collaboration with Recursion
PremiumCompany Announcements
Exscientia Set for Strategic Acquisition by Recursion
PremiumCompany Announcements
Exscientia Plc Backs Acquisition by Recursion Pharmaceuticals
PremiumCompany Announcements
Exscientia’s Strategic Merger and Pipeline Progress
Bulls Say, Bears Say
Bulls Say
Innovative Drug DiscoveryExscientia's AI-driven drug discovery platform incorporates live patient sample data and active machine learning to maximize the information gained from a given inquiry.
Promising Clinical PipelineCombining the pipelines and partnership portfolios of Exscientia and Recursion positions the combined entity for up to 10 clinical readouts and approximately $200M in potential milestone payments.
Strategic Merger BenefitsThe merger is a solid outcome for Exscientia that expands the resources at their disposal and adds multiple clinical-stage assets to their portfolio.
Bears Say
Financial PerformanceReturn on Equity for EXAI over the trailing twelve months is -34.98%.
Stock DowngradeThe stock rating for EXAI has been downgraded to Equal Weight following the announced all-stock transaction with Recursion Pharmaceuticals.
Transaction RisksRisks associated with EXAI include competition in the AI space, potential negative clinical data updates, and the possibility of the transaction with Recursion Pharma not closing.
---
Ownership Overview
15.56%
Insiders
0.06% Mutual Funds
4.35% Other Institutional Investors
79.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXAI FAQ
What was Exscientia Plc’s price range in the past 12 months?
Exscientia Plc lowest stock price was $3.80 and its highest was $7.91 in the past 12 months.
What is Exscientia Plc’s market cap?
Currently, no data Available
When is Exscientia Plc’s upcoming earnings report date?
Exscientia Plc’s upcoming earnings report date is Nov 13, 2024 which is in 3 days.
How were Exscientia Plc’s earnings last quarter?
Exscientia Plc released its earnings results on Aug 15, 2024. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.239 by -$0.121.
Is Exscientia Plc overvalued?
According to Wall Street analysts Exscientia Plc’s price is currently Overvalued.
Does Exscientia Plc pay dividends?
Exscientia Plc does not currently pay dividends.
What is Exscientia Plc’s EPS estimate?
Exscientia Plc’s EPS estimate is -$0.21.
How many shares outstanding does Exscientia Plc have?
Exscientia Plc has 129,255,310 shares outstanding.
What happened to Exscientia Plc’s price movement after its last earnings report?
Exscientia Plc reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.239. Following the earnings report the stock price went down -2.752%.
Which hedge fund is a major shareholder of Exscientia Plc?
Among the largest hedge funds holding Exscientia Plc’s share is Platinum Investment Management. It holds Exscientia Plc’s shares valued at 10M.
---
Exscientia Plc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.35 (-1.65% Downside)
$5.35 (-1.65% Downside)
Blogger Sentiment
Bullish
EXAI Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.98%
12-Months-Change
Fundamentals
Return on Equity
-36.01%
Trailing 12-Months
Asset Growth
-22.81%
Trailing 12-Months
Company Description
Exscientia Plc
Exscientia PLC is an artificial intelligence-driven pharma tech company committed to discovering, designing, and developing drugs. Its patient-first AI process is comprised of Precision Target, Precision Design, Precision Experiment, and Precision Medicine. Its revenue is generated from Service fees related to drug discovery collaboration agreements it is utilizing its proprietary technology to develop novel Intellectual Property (IP); and Licensing fees related to drug discovery agreements.
---
EXAI Company Deck
---
EXAI Earnings Call
Q1 2024
0:00 / 0:00
---
EXAI Stock 12 Month Forecast
Average Price Target
$5.35
▼(-1.65% Downside)
Technical Analysis
---